- Home
- PTGX vs RCKT Comparison
PTGX vs RCKT Comparison
Compare PTGX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | RCKT |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 428.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PTGX | RCKT |
|---|---|---|
| Price | $82.61 | $3.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $93.00 | $29.12 |
| AVG Volume (30 Days) | 767.1K | ★ 2.2M |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $209,217,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $409.41 | N/A |
| P/E Ratio | $115.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.70 | $2.19 |
| 52 Week High | $96.54 | $11.45 |
Technical Indicators
Market Signals| Indicator | PTGX | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 50.55 |
| Support Level | $79.87 | $3.43 |
| Resistance Level | $85.50 | $3.96 |
| Average True Range (ATR) | 3.25 | 0.24 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 45.22 | 31.45 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.